Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Aims: To systematically review the scientific literature for evidence concerning the clinical use of botulinum toxin (BTX) for the management of various temporomandibular disorders (TMDs).
Methods: A comprehensive literature search was conducted in the Medline, Web of Science, and Cochrane Library databases to find randomized clinical trials (RCT) published between 2000 and the end of April 2021 investigating the use of BTX to treat TMDs. The selected articles were reviewed and tabulated according to the PICO (patients/problem/population, intervention, comparison, outcome) format.
Results: A total of 24 RCTs were selected. Nine articles used BTX injections to treat myofascial pain, 4 to treat temporomandibular joint (TMJ) articular TMDs, 8 for the management of bruxism, and 3 to treat masseter hypertrophy. A total of 411 patients were treated by injection of BTX. Wide variability was found in the methods of injection and in the doses injected. Many trials concluded superiority of BTX injections over placebo for reducing TMD pain levels and improving maximum mouth opening; however, this was not universal.
Conclusion: There is good scientific evidence to support the use of BTX injections for treatment of masseter hypertrophy and equivocal evidence for myogenous TMDs, but very little for TMJ articular disorders. Studies with improved methodologic design are needed to gain better insight into the utility and effectiveness of BTX injections for treating both myogenous and TMJ articular TMDs and to establish suitable protocols for treating different TMDs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10586579 | PMC |
| http://dx.doi.org/10.11607/ofph.3023 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Engineered Exosomes Complexed with Botulinum Toxin Type A for Enhanced Anti-Aging Effects on Skin.
Biology (Basel)
August 2025
Key Laboratory of Tropical Translational Medicine of Ministry of Education & Key Laboratory of Brain Science Research Transformation in Tropical Environment of Hainan Province, School of Basic Medicine and Life Sciences, Hainan Medical University, Haikou 571199, China.
Skin aging is commonly characterized by increased wrinkles, loss of elasticity, and hyperpigmentation, significantly affecting personal appearance and quality of life. Although botulinum toxin type A (BTX-A) has been widely applied in cosmetic anti-wrinkle treatments, its intrinsic cytotoxicity limits broader clinical applications. In this study, we developed a novel exosome-based BTX-A composite delivery system designed to synergize the anti-aging properties of exosomes with the wrinkle-reducing effects of BTX-A while reducing toxicity.
View Article and Find Full Text PDFInvestigating the correlation between the blepharospasm disability index and botulinum neurotoxin dosage for benign essential blepharospasm and hemifacial spasm.
Orbit
September 2025
Orbital and Ophthalmic Plastic Surgery Division, Department of Ophthalmology, University of California, Los Angeles, California, USA.
Purpose: The purpose of this study is to evaluate the association between the blepharospasm disability index (BSDI) and botulinum neurotoxin (BTX) dosage for patients affected by either benign essential blepharospasm or hemifacial spasm.
Methods: Cross-sectional cohort study evaluating adult patients diagnosed with benign essential blepharospasm or hemifacial spasm who completed a BSDI evaluation prior to receiving same-day therapeutic BTX injections. Primary outcome measures included BSDI score and number of BTX units.
Optimizing the Injection Schema for Higher Doses of OnabotulinumtoxinA (BTX-A) in the Office Setting: A Randomized Prospective Trial for Patients With Neurogenic Lower Urinary Tract Dysfunction and Idiopathic Overactive Bladder.
Neurourol Urodyn
August 2025
Department of Urology, Houston Methodist Hospital, Weill Cornell Medical College, Houston, Texas, USA.
Background: OnabotulinumtoxinA (BTX-A) decreases urge urinary incontinence (UUI) and improves quality of life for patients with idiopathic overactive bladder (IOAB) and neurogenic lower urinary tract dysfunction (NLUTD). Limited research exists optimizing injection techniques for higher doses (200- or 300-units) of BTX-A in the clinic setting. Optimization with less injections could improve satisfaction and willingness to repeat injections while maintaining effectiveness.
View Article and Find Full Text PDFAtrophy Masseter Recovery by Electrical Stimulation Mediated M2-Like Macrophage Polarisation via JAK/PI3K/AKT Pathway.
J Cachexia Sarcopenia Muscle
August 2025
College & Hospital of Stomatology, Anhui Medical University, Key Lab. of Oral Diseases Research of Anhui Province, Hefei, China.
Background: Atrophy of the masseter muscle can result in an aged facial appearance and diminished chewing function. Electrical stimulation (ES) is known for its ability to facilitate tissue healing and functional recovery, but its precise role in the repair of atrophic masseter muscles remains incompletely understood.
Methods: We induced masseter muscle atrophy in rats through botulinum toxin (BTX) injection and subsequently treated the animals with or without ES.
Efficacy and Durability of the Association of Botox and Skinvive in the Treatment of Moderate/Severe Wrinkles in the Periorbital Region: A Randomized, Controlled, Double-Blind, Split-Face Clinical Study.
J Cosmet Dermatol
August 2025
Department of Dentistry, Ingá University Center, Paraná, Brazil.
Background: The combined efficacy and durability of botulinum toxin A (BTX) and hyaluronic acid fillers (HA) for canthal wrinkles have not been thoroughly evaluated in randomized clinical trials.
Aims: This study evaluated the efficacy, safety, and durability of the combined treatment protocol of onabotulinumtoxinA and Juvederm Volite VYC-12 (Skinvive) for moderate and severe canthal lines.
Methods: This randomized double-blinded split-face trial included 25 women with periorbital dynamic wrinkles at severity levels II-IV according to the Merz 5-point scale.